Craif's Urine Cancer Risk Test 'MySignal Scan' Introduced at Medical Excellence International General Hospital's SOPHIA Health Check-up
Key facts
- Craif's Urine Cancer Risk Test 'MySignal Scan' Introduced at Medical Excellence International General Hospital's SOPHIA Health Check-up
- Craif Inc., a bio-AI startup, announces that its urine cancer risk test, 'MySignal Scan,' will be newly introduced as an optional examination for health check-ups at Medical Excellence International General Hospital's SOPHIA Health Check-up. This introduction aims to expand less physically burdensome testing options, lower the barrier to undergoing screenings, and contribute to cancer prevention and early detection.
- Source: PR Times
- Date: June 10, 2026
Direct answer
Craif Inc., a bio-AI startup, announces that its urine cancer risk test, 'MySignal Scan,' will be newly introduced as an optional examination for health check-ups at Medical Excellence International General Hospital's SOPHIA Health Check-up. This introduction aims to expand less physically burdensome testing options, lower the barrier to undergoing screenings, and contribute to cancer prevention and early detection.
- Citation
- Craif's Urine Cancer Risk Test 'MySignal Scan' Introduced at Medical Excellence International General Hospital's SOPHIA Health Check-up (June 10, 2026), PR Times
- Source
- PR Times
- Date
- June 10, 2026
Craif Inc., a bio-AI startup, announces that its urine cancer risk test, 'MySignal Scan,' will be newly introduced as an optional examination for health check-ups at Medical Excellence International General Hospital's SOPHIA Health Check-up. This introduction aims to expand less physically burdensome testing options, lower the barrier to undergoing screenings, and contribute to cancer prevention and early detection.
📋 Article Processing Timeline
- 📰 Published: June 10, 2026 at 10:00
- 🔍 Collected: June 10, 2026 at 10:30 (30 min after Published)
- 🤖 AI Analyzed: June 12, 2026 at 16:52 (54h 21m after Collected)
This introduction aims to expand less physically burdensome testing options, lower the barrier to undergoing screenings, and contribute to cancer prevention and early detection.
◼️ About 'MySignal Scan'
'MySignal Scan' is a test that analyzes microRNAs in urine using AI to evaluate the risk of 10 types of cancer*, by cancer type, from Stage 1. It is possible to test without burdening the body simply by collecting urine.
For details, please visit our website.
https://misignal.jp/
'MySignal Scan' is not a medical device. It determines risk by statistically calculating analyzed information and is not a substitute for a 'diagnosis' of whether one has cancer as a medical act. Even if the risk is determined to be low, it does not mean that cancer is absent or that cancer will not occur in the future.
* Ovarian and breast cancer are testable for women only, and prostate cancer is testable for men only.
■ About Craif
Craif is a bio-AI startup founded in 2018, dedicated to the early detection of cancer. By integrating its proprietary analysis technology platform 'NANO IP®︎ (NANO Intelligence Platform),' which detects various biomarkers such as DNA and microRNA from body fluids including urine with high precision, with AI technology, the company develops innovative tests that enable ultra-early detection, early treatment, and early recovery from cancer. By widely delivering the power of biotechnology and AI to society, Craif promotes its vision of 'realizing a society where people can live out their natural lifespan.'
【Company Profile】
Company Name: Craif Inc. (Pronunciation: Kuraifu)
Representative: Ryuichi Ono, Representative Director and CEO
Established: May 2018
Capital: 100 million yen (as of April 1, 2025)
Business: Research and development of next-generation tests for early detection of diseases, primarily in the cancer field, and for the realization of personalized medicine; provision of the urine cancer risk test 'MySignal®.'
Headquarters: THE PORTAL iidabashi B1F, 8-30 Shinkawa-cho, Shinjuku-ku, Tokyo
URL: https://craif.com/
FAQ
What types of cancer can 'MySignal Scan' detect?
It assesses the risk for 10 types of cancer, including pancreatic cancer. However, ovarian and breast cancer are for women only, and prostate cancer is for men only.
Is the test painful?
No, it involves only collecting urine, so there is minimal physical burden.
Can this test diagnose cancer?
No, this is a risk assessment test and not a substitute for a medical 'diagnosis.' A low risk does not rule out the possibility of cancer.
Which hospital has introduced this test?
Medical Excellence International General Hospital's SOPHIA Health Check-up. It is offered as an option for health check-ups.
What are Craif's technological strengths?
Their strength lies in combining proprietary 'NANO IP®︎' technology for high-precision detection of microRNAs in urine with AI to aim for ultra-early cancer detection.